Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Canuck Dave who wrote (18679)	8/5/1999 1:08:00 PM
From: Wes Stevens	Respond to of 56535

No not too harsh at all dave. The market coming back this morning was surprising. I should have never let myself get into that position. I bought most of the enft at 38 1/2 and watched it go all the way to 45. Then watched it tank all the way to 29 1/4 this morning. To watch at stock drop like that is not the way it is supposed to be done. I have to get more discipline or I will be watching from the sidelines - broke

To: Canuck Dave who wrote (18679)	8/5/1999 1:15:00 PM
From: Wes Stevens	Read Replies (1) \| Respond to of 56535

IMCL up 2 3/4 NEW YORK, Aug. 5 /PRNewswire/ -- The following is being issued by Oscar Gruss & Son Incorporated, a member of the National Association of Securities Dealers, CRD number 2091: Oscar Gruss & Son Incorporated initiates coverage on ImClone Systems (NASDAQ:IMCL; $21-7/16) with a SPECULATIVE BUY rating. In a new report, Akhtar Samad, M.D., Ph.D., senior equity research analyst at Oscar Gruss, provides a detailed examination of ImClone Systems (IMCL), a development stage biotechnology company that researches, develops and will market primarily biological products for the treatment of cancer. The report projects that positive newsflow over the next 12 months from multiple ongoing advanced clinical trials in various cancers for ImClone's lead products, a monoclonal antibody (C225) and a cancer vaccine (BEC-2), should lead to one or more regulatory filings by mid-2000 and corporate profitability by late 2002/early 2003. The analyst expects EPS to grow from ($0.38) in 1999 to $1.19 in 2003.